世界のコンパニオン診断市場

当レポートでは、世界のコンパニオン診断市場について調査し、市場の動向とセグメント別概要、地域別動向、および市場に参入主要企業のプロファイルと競合動向についてまとめています。

第1章 イントロダクション、調査方法、製品定義

第2章 業界概要

第3章 市場動向と課題

• 個別化医療の重要性が市場の主な牽引因子
• コンパニオン診断が個別化医療の道をリード
• 個別化医療の研究開発におけるコスト削減がコンパニオン診断を可能に
• コンパニオン診断による標的療法の改良　他

第4章 製品概要

• 個別化医療における診断
• 遺伝子検査
• コンパニオン診断
• コンパニオン診断：どのように作用するのか
• コンパニオン診断で使用される技術
• コンパニオン診断としてのバイオマーカー
• コンパニオン診断の応用概要
• 薬剤開発プロセスにおけるコンパニオン診断の役割
• 治験におけるコンパニオン診断
• 治療分野におけるコンパニオン診断
• 腫瘍学におけるコンパニオン診断
• 炎症性疾患におけるコンパニオン診断
• 感染症におけるコンパニオン診断
• 薬剤代謝におけるコンパニオン診断
• ステークホルダーの見解　他

第5章 競合環境

• 世界的参入企業
• 製品認可／上市
• 近年の業界活動

第6章 世界市場見通し

第7章 地域別市場見通し

• 米国
• カナダ
• 日本
• 欧州
• アジア太平洋地域
• ラテンアメリカ
• その他の諸国

第8章 企業プロファイル

This report analyzes the worldwide markets for Companion Diagnostics in US$ Million. The Global market is further analyzed by the following Therapeutic Areas: Oncology, Neurology, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 80 companies including many key and niche players such as -

Abbott Molecular
Agilent Technologies, Inc.
bioMerieux SA
Danaher Corporation
F. Hoffmann-La Roche Ltd.
Merck & Co. Inc..

Table of Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study

2. INDUSTRY OVERVIEW

• Companion Diagnostics: An Introductory Prelude
• Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development
• Broader Scope and Applications Rev Up Growth Opportunities
• Healthy Growth Projected over the Next Few Years
• Developed Regions: Key Revenue Contributors
• Table 1: Developed Regions Account for Lion's Share of World CDx Market: Percentage Breakdown of Revenues for Developed and Developing Regions (2018E & 2022P) (includes corresponding Graph/Chart)
• Market Witnesses Fast Paced Growth in Developing Regions
• Table 2: Global CDx Market - Geographic Regions Ranked by CAGR (Revenues) for 2015-2022: Asia-Pacific, Latin America, Rest of World, Canada, Europe, US and Japan (includes corresponding Graph/Chart)
• Northbound Trajectory in R&D Spending Creates Conducive Environment
• Table 3: Global Pharmaceutical R&D Spending (in US$ Billion) for the Years 2010 through 2017 (includes corresponding Graph/Chart)
• Table 4: Leading Countries with Highest Healthcare Spending as a Percentage (%) of GDP (2016) (includes corresponding Graph/Chart)
• Table 5: Per Capita Healthcare Spending (in US$) in Select Countries for the Year 2016 (includes corresponding Graph/Chart)
• Prevailing Economic Scenario Favors Funding Pattern
• Table 6: World Real GDP Growth Rates in % (2016-2019P): Breakdown by Country/Region (includes corresponding Graph/Chart)

3. MARKET TRENDS, GROWTH DRIVERS & ISSUES

• Growing Significance of Personalized Medicine Remains a Major Market Driver
• Table 7: World Market for Personalized Medicine: Breakdown of Revenues (in US$ Billion) for 2014, 2018E and 2022P (includes corresponding Graph/Chart)
• Table 8: World Personalized Medicine Market by Region/Country (2018E): Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World (includes corresponding Graph/Chart)
• Table 9: Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population (includes corresponding Graph/Chart)
• Companion Diagnostics Lead the Way to Personalized Medicine
• Significant Cost Reductions in Personalized Medicine R&D Made Possible with CDx
• Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum
• Herceptin Lays the Road for Companion Diagnostics
• Table 10: Global Companion Diagnostic-Associated Drug Market by Drug (2016): Percentage Breakdown of Revenue for Erbitux, Gleevec, Herceptin, Iressa, Tarceva, Tasigna, & Others (includes corresponding Graph/Chart)
• Oncology - Dominant Therapy Area for CDx
• Table 11: Percentage (%) Share of Oncology in Worldwide CDx Revenues (2018E & 2022P) (includes corresponding Graph/Chart)
• Table 12: Oncology CDx Market by Cancer Type (2016): Percentage Breakdown of Revenues for Breast, Colorectal, Gastric, Lung, Melanoma, and Other Cancers (includes corresponding Graph/Chart)
• Rising Incidence of Cancer Propels the Need for CDx Tests
• Table 13: Global Cancer Incidence (2015): Number of New Cancer Cases in Thousands by Type and Gender (includes corresponding Graph/Chart)
• Table 14: Global Cancer Mortality (2015): Number of Cancer Related Deaths in Thousands by Type and Gender (includes corresponding Graph/Chart)
• Table 15: Worldwide Incidence of Cancer in Millions: 2012, 2020P & 2030P (includes corresponding Graph/Chart)
• Technology Advancements to Widen CDx Use Case
• PCR: Dominant Technology Type for CDx Testing
• QuantaLife ddPCR(tm) System: Breakthrough Innovation in the PCR CDx Vertical
• Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing
• Significant Role of Biomarkers in Companion Diagnostics
• Critical Healthcare Needs of Aging Population Underpin CDx Sales
• Table 16: Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)
• Table 17: Global Population Statistics for the 60+ Age Group by Region: 2017 (includes corresponding Graph/Chart)
• Table 18: Global Population Statistics for the 65+ Age Group by Select Countries: 2016 (includes corresponding Graph/Chart)
• Table 19: Global Life Expectancy at Birth (Years) by Geographic Region: 1950-2050 (includes corresponding Graph/Chart)
• Regulatory Scenario Favors CDx Market
• List of Key Market Requirements for CDx in US, Canada and Europe
• Resolving Prevailing Challenges: Critical for Future Growth of CDx Market
• Key Issues in a Nutshell

4. PRODUCT OVERVIEW

• Diagnostics in Personalized Medicine
• Genetic Tests
• Companion Diagnostics
• Companion Diagnostics: What Makes them Work
• Techniques Used in Companion Diagnostics
• Biomarkers as Companion Diagnostics
• Applications of Companion Diagnostics at a Glance
• Role of Companion Diagnostics in the Drug Development Process
• Companion Diagnostics in Clinical Trials
• Companion Diagnostics in Select Therapeutic Areas
• Companion Diagnostics in Oncology
• Select Companion Diagnostics in Cancer
• Oncotype DX(r)
• Quantitative Recurrence Score
• Oncotype DX Test in Oncology: Stage of Intervention in Adjuvant Treatment Decision
• Eligibility
• The Test Procedure
• Molecular Grade Index (MGISM) (bioTheranostics)
• Breast Cancer IndexSM (bioTheranostics)
• KRAS Testing
• HER2 Testing for Herceptin Treatment in Breast Cancer
• Assays Used for HER2 Testing
• MammaPrint
• The EGFRx(tm) Assay to Aid Cancer Treatment
• c-Kit pharmDx Assay to Aid Cancer Treatment (DakoCytomation)
• Companion Diagnostics in Inflammatory Diseases
• PROMETHEUS(r) IBD Serology 7 for Irritable Bowel Disease
• Companion Diagnostics in Infectious Diseases
• Trofile(r) Assay to Aid in HIV Treatment
• Companion Diagnostics in Drug Metabolism
• AmpliChip(r) CYP450 Test
• HILOmet PhyzioType(tm) System (Genomas)
• Warfarin Sensitivity Test
• Companion Diagnostics: In Stakeholders' Perspective
• Pharmaceutical Company (Drug Manufacturer)
• Diagnostic Company (Companion Diagnostic Manufacturer)
• Patients
• Physician/Healthcare Professional
• Payer

5. COMPETITIVE LANDSCAPE

• Leading Players in the World Companion Diagnostics Market
• Vendors Rely on Collaborations to Widen Market Footprint
• Select CDx Collaborative Deals Announced in the Recent Past
• 5.1. Focus on Select Global Players
• Abbott Molecular (USA)
• Agilent Technologies, Inc. (USA)
• bioMerieux SA (France)
• Danaher Corporation (USA)
• Cepheid (USA)
• Leica Biosystems Nussloch GmbH (Germany)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Foundation Medicine, Inc. (USA)
• Laboratory Corporation of America(r) Holdings (USA)
• Merck & Co. Inc. (USA)
• Myriad Genetics, Inc. (USA)
• NeoGenomics, Inc. (USA)
• QIAGEN N.V. (Netherlands)
• Quest Diagnostics, Inc. (USA)
• Thermo Fisher Scientific, Inc. (USA)
• 5.2 Product Approvals/Launches
• Foundation Medicine Unveils FoundationOne CDx(tm)
• Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma
• Roche Receives US FDA Approval for PMA Supplement for cobas(r) EGFR Mutation Test v2
• Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis(r) Diagnostic System in Japan
• Roche Wins US FDA Approval for cobas(r) EGFR Mutation Test v2 as a CDx with IRESSA(r)
• Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx(r)
• MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug
• Thermo Fisher Scientific Receives US FDA Approval for Oncomine(tm) Dx Target Test for Three NSCLC Treatments
• 5.3 Recent Industry Activity
• Roche to Fully Acquire Foundation Medicine
• Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo
• Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific
• Qiagen and Freenome to Develop NGS-based Companion Diagnostics
• Bristol-Myers Squibb Joins Hands with Illumina
• QIAGEN to Acquire STAT-Dx
• PPD forms Strategic Alliance with NeoGenomics
• LabCorp Collaborates with Unilabs
• Merck KGaA and ArcherDX to Develop NGS-based CDx Assay
• QIAGEN Teams Up with SRL
• Shuwen Biotech Partners with Bliss Biopharmaceutical
• Foundation Medicine and Merck to Develop CDx Tests
• Pierre Fabre Extends CDx Collaboration with Roche
• Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China
• Foundation Medicine Inks CDx Partnership Deal with Pfizer
• NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program
• LabCorp(r) Inaugurates New Covance CDx Facility in North Carolina
• Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene
• Myriad Genetics to Provide BRACAnalysis CDx(r) to Clovis Oncology
• Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems
• Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines
• Thermo Fisher Scientific Partners with Agios Pharmaceuticals
• Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program
• Bristol-Myers Squibb Joins Hands with GRAIL
• Bristol-Myers Squibb Teams Up with QIAGEN

6. GLOBAL MARKET PERSPECTIVE

• Table 20: World Recent Past, Current & Future Analysis for Companion Diagnostics Market by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
• Table 21: World 5-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2018 & 2022 (includes corresponding Graph/Chart)
• By Application
• Table 22: World Recent Past, Current & Future Analysis for Companion Diagnostics Market by Application Segment - Oncology, Neurology, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
• Table 23: World 5-Year Perspective for Companion Diagnostics by Application Segment - Percentage Breakdown of Dollar Revenues for Oncology, Neurology, and Others Markets for Years 2018 & 2022 (includes corresponding Graph/Chart)

7. REGIONAL MARKET PERSPECTIVE

• 7.1 The United States
• A. Market Analysis
• The United States: Prime Market for Companion Diagnostics
• Table 24: US Accounts for over 2/5th of World CDx Market: Percentage Breakdown of CDx Revenues for US and Rest of World (2018E and 2022P) (includes corresponding Graph/Chart)
• Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities
• Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics
• Table 25: Cancer Incidence in the US by Gender (2018E): Estimated New Cases for Men and Women (includes corresponding Graph/Chart)
• Table 26: Cancer Incidence in the US by Gender (2018E): Estimated Deaths for Men and Women (includes corresponding Graph/Chart)
• Pioneering Efforts in Oncology CDx Testing
• Robust Personalized Medicine Market Offers Potential
• Table 27: US Personalized Medicine Market: Breakdown of Revenues (in US$ Billion) for 2014, 2018E and 2022P (includes corresponding Graph/Chart)
• Biomarkers: A Novel Paradigm in Companion Diagnostics
• List of US-FDA Approved Biomarkers for Cancer
• Ageing Demographics: A Key Market Driver
• Table 28: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
• Competitive Scenario
• Regulatory Overview
• FDA Requirements in Drug Development Fuel Demand
• Table 29: Rise in CDx Numbers Over the Years: Number of FDA-Approved Drugs Requiring CDx for Year 1998, 2005, 2008 & 2016 (includes corresponding Graph/Chart)
• List of FDA-Approved Companion Diagnostics: As of H1 2018
• Table 30: Leading FDA-Approved CDx Drugs in the US (2016): Percentage Breakdown of Revenues for Erbitux/Vectibix, Gleevec, Herceptin, Lynparza, Mekinist+Tafinlar, Perjeta, Tarceva, and Others (includes corresponding Graph/Chart)
• B. Market Analytics
• Table 31: The US Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
• Table 32: The US Historic Review for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
• 7.2 Canada
• A. Market Analysis
• Higher R&D Spending to Underpin CDx Revenues
• Cancer Incidence in Canada: Opportunity Indicator for Companion Diagnostics
• Table 33: New Cancer Cases in Canada by Gender (2017): Breakdown of Cancer Incidence for Male and Female Population (in Thousands) (includes corresponding Graph/Chart)
• Table 34: Cancer Related Deaths in Canada (2017): Percentage Breakdown of Number of Deaths by Gender and Affected Site (includes corresponding Graph/Chart)
• Regulatory Scenario
• B. Market Analytics
• Table 35: Canadian Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
• 7.3 Japan
• A. Market Analysis
• Graying Population Spurs Growth
• Table 36: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)
• Table 37: Japanese Population by Age Group (2017): Percentage Breakdown for 0-14 Years, 15-24 Years, 25-54 Years, 55-64 Years, 65 Years and Above (includes corresponding Graph/Chart)
• B. Market Analytics
• Table 38: Japanese Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
• Table 39: Japanese Historic Review for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
• 7.4 Europe
• A. Market Analysis
• A Mature yet Growing Market
• CDx Gain from Healthy Momentum in Research Programs
• Growing Role of Personalized Medicine Bodes Well for CDx
• Table 40: Europe Personalized Medicine Market: Breakdown of Revenues (in US$ Billion) for 2014, 2018E and 2022P (includes corresponding Graph/Chart)
• Cancer Incidence in Europe: An Opportunity Indicator
• Table 41: Number of New Cancer Cases in Europe: 2012-2030 (includes corresponding Graph/Chart)
• Ageing Population Drives Demand
• Table 42: EU-28 Country-wise Statistics of 65+ Population as % of Total Population: 2016 (includes corresponding Graph/Chart)
• Regulatory Scenario in Europe
• B. Market Analytics
• Table 43: European Recent Past, Current & Future Analysis for Companion Diagnostics Market by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
• Table 44: European Historic Review for Companion Diagnostics Market by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
• Table 45: European 5-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Dollar Revenues for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2018 & 2022 (includes corresponding Graph/Chart)
• 7.4.1 France
• Market Analysis
• Table 46: French Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
• Table 47: French Historic Review for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
• 7.4.2 Germany
• Market Analysis
• Table 48: German Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
• Table 49: German Historic Review for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
• 7.4.3 Italy
• Market Analysis
• Table 50: Italian Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
• Table 51: Italian Historic Review for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
• 7.4.4 The United Kingdom
• Market Analysis
• Table 52: The UK Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
• Table 53: The UK Historic Review for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
• 7.4.5 Spain
• Market Analysis
• Table 54: Spanish Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
• Table 55: Spanish Historic Review for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
• 7.4.6 Rest of Europe
• Market Analysis
• Table 56: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
• Table 57: Rest of Europe Historic Review for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
• 7.5 Asia-Pacific
• A. Market Analysis
• A Rapidly Growing Market
• Uptrend in IVD Sales Augurs Well for Market Growth
• B. Market Analytics
• Table 58: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics Market by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
• Table 59: Asia-Pacific 5-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Dollar Revenues for China and Rest of Asia-Pacific Markets for Years 2018 & 2022 (includes corresponding Graph/Chart)
• 7.5.1 China
• A. Market Analysis
• Breast Cancer CDx: Dominant Category
• Laboratory Equipment & Supplies Sector in China: An Overview
• B. Market Analytics
• Table 60: Chinese Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
• 7.5.2 Rest of Asia-Pacific
• Market Analysis
• Table 61: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
• 7.6 Latin America
• Market Analysis
• Table 62: Latin American Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
• 7.7 Rest of World
• Market Analysis
• Table 63: Rest of World Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

8. COMPANY PROFILES

• Total Companies Profiled: 80 (including Divisions/Subsidiaries - 89) The United States (53) Canada (2) Europe (28) - France (5) - Germany (4) - The United Kingdom (9) - Spain (1) - Rest of Europe (9) Asia-Pacific (Excluding Japan) (5) Middle East (1)